BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 30344795)

  • 41. Microarray profile of circular RNAs identifies hsa_circRNA_102459 and hsa_circRNA_043621 as important regulators in oral squamous cell carcinoma.
    Deng W; Peng W; Wang T; Chen J; Qiu X; Fu L; Zhu S
    Oncol Rep; 2019 Dec; 42(6):2738-2749. PubMed ID: 31638251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circ_LPAR3 promotes the progression of oral squamous cell carcinoma (OSCC).
    Li L; Yin Y; Nan F; Ma Z
    Biochem Biophys Res Commun; 2022 Jan; 589():215-222. PubMed ID: 34922206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma.
    Bai S; Wu Y; Yan Y; Shao S; Zhang J; Liu J; Hui B; Liu R; Ma H; Zhang X; Ren J
    Sci Rep; 2020 Aug; 10(1):13659. PubMed ID: 32788609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel circular RNA (hsa_circRNA_102336), a plausible biomarker, promotes the tumorigenesis by sponging miR-515-5p in human bladder cancer.
    Gong P; Xu R; Zhuang Q; He X
    Biomed Pharmacother; 2020 Jun; 126():110059. PubMed ID: 32208321
    [TBL] [Abstract][Full Text] [Related]  

  • 45. circ-PKD2 inhibits carcinogenesis via the miR-204-3p/APC2 axis in oral squamous cell carcinoma.
    Gao L; Zhao C; Li S; Dou Z; Wang Q; Liu J; Ren W; Zhi K
    Mol Carcinog; 2019 Oct; 58(10):1783-1794. PubMed ID: 31206208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Downregulated hsa_circ_0077837 and hsa_circ_0004826, facilitate bladder cancer progression and predict poor prognosis for bladder cancer patients.
    Shen C; Wu Z; Wang Y; Gao S; Da L; Xie L; Qie Y; Tian D; Hu H
    Cancer Med; 2020 Jun; 9(11):3885-3903. PubMed ID: 32250047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hsa_circRNA_0001971 contributes to oral squamous cell carcinoma progression via miR-186-5p/Fibronectin type III domain containing 3B axis.
    Zhang J; Peng Y; Jiang S; Li J
    J Clin Lab Anal; 2022 Mar; 36(3):e24245. PubMed ID: 35060189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MicroRNA-155-5p is associated with oral squamous cell carcinoma metastasis and poor prognosis.
    Baba O; Hasegawa S; Nagai H; Uchida F; Yamatoji M; Kanno NI; Yamagata K; Sakai S; Yanagawa T; Bukawa H
    J Oral Pathol Med; 2016 Apr; 45(4):248-55. PubMed ID: 26307116
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circular RNA_0076977 contributes to oral squamous cell carcinoma progression through mediating microRNA-802 axis.
    Hei N; Chen Y; Peng S; Bao Y; Jin L
    Arch Oral Biol; 2022 Dec; 144():105567. PubMed ID: 36265392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EIF4A3-regulated hsa_circ_0001445 can inhibit the progression of laryngeal squamous cell carcinoma via hsa-miR-432-5p-dependent up-regulation of RGMA expression.
    Yu M; Cao H; Yang J; Liu T; Gao J; Wang B
    Cell Cycle; 2023 Sep; 22(18):2038-2056. PubMed ID: 37902305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Circular RNA hsa_circ_0000277 promotes tumor progression and DDP resistance in esophageal squamous cell carcinoma.
    Cheng J; Zhang R; Yan M; Li Y
    BMC Cancer; 2022 Mar; 22(1):238. PubMed ID: 35241028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circle RNA hsa_circRNA_100290 serves as a ceRNA for miR-378a to regulate oral squamous cell carcinoma cells growth via Glucose transporter-1 (GLUT1) and glycolysis.
    Chen X; Yu J; Tian H; Shan Z; Liu W; Pan Z; Ren J
    J Cell Physiol; 2019 Nov; 234(11):19130-19140. PubMed ID: 31187488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Propofol prevents the aggressive progression of oral squamous cell carcinoma via regulating circ_0005623/miR-195-5p/HOXB7 axis.
    Cao C; Zhang X; Xu Y
    Biotechnol Appl Biochem; 2022 Jun; 69(3):1015-1028. PubMed ID: 33894003
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circular RNA hsa_circ_0081343 promotes trophoblast cell migration and invasion and inhibits trophoblast apoptosis by regulating miR-210-5p/DLX3 axis.
    Wang H; Luo C; Wu X; Zhang J; Xu Z; Liu Y; Li B; Li J; Xie J
    Reprod Biol Endocrinol; 2021 Aug; 19(1):123. PubMed ID: 34365964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening and identification of epithelial-to-mesenchymal transition-related circRNA and miRNA in prostate cancer.
    Yan Z; Xiao Y; Chen Y; Luo G
    Pathol Res Pract; 2020 Feb; 216(2):152784. PubMed ID: 31882179
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Upregulated circ_0002141 facilitates oral squamous cell carcinoma progression via the miR-1231/EGFR axis.
    Wangzhou K; Lu Z; Lai Z; Fu W; Liu C; Tan Y; Hao C
    Oral Dis; 2023 Apr; 29(3):902-912. PubMed ID: 34739167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circ_0058063 contributes to oral squamous cell carcinoma development by sponging miR-145-5p and upregulating SERPINE1.
    Yu J; Lou Y; Hou M; Ma X; Wang L
    J Oral Pathol Med; 2022 Aug; 51(7):630-637. PubMed ID: 35778962
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sevoflurane inhibits oral squamous carcinoma progression by modulating the circ_0000857/miR-145-5p axis.
    Feng Y; Qi Y; Zhang Q; Zhang M
    Chem Biol Drug Des; 2024 Jan; 103(1):e14362. PubMed ID: 37770418
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of hsa_circ_0002024 as a prognostic competing endogenous RNA (ceRNA) through the hsa_miR_129-5p/Anti-Silencing Function 1B Histone Chaperone (ASF1B) axis in renal cell carcinoma.
    Chen Z; Ou D; Huang Z; Shen P
    Bioengineered; 2021 Dec; 12(1):6579-6593. PubMed ID: 34516341
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of aberrant circular RNA expression and its potential clinical value in primary great saphenous vein varicosities.
    Zhang W; Li L; Si Y; Shi Z; Zhu T; Zhuang S; Fu W
    Biochem Biophys Res Commun; 2018 May; 499(2):328-337. PubMed ID: 29577902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.